BioCryst is profitable with Orladeyo delivering over $2B in sales since 2020 and guiding up to $645M this year. The company plans growth through external asset acquisitions, signaling a shift from internal pipelines to a more acquisitive rare-disease strategy. Rare Ventures, backed by Mellon Foundation, highlights rising capital support for de-risked assets that could feed BioCryst and peers.
BioCryst says it will wind down internal drug discovery and close its Alabama research facility by end-2026 as it shifts to external partnerships to advance its rare-disease portfolio and reduce costs. The move aims to lower operating burn and redirect resources toward collaborations, potentially implying longer development timelines but possible milestone-based value creation through licensing.
FDA approves new oral pellet formulation of BCRX's drug for young children. This new indication could significantly increase market for BCRX's product.
BCRX reported Q1 2025 sales of $145.50 million, up 52.7% YoY. Orladeyo's revenue increased to $134.2 million, contributing significantly. Net income turned positive at $32 thousand, contrasting last year's loss. 2025 Orladeyo revenue guidance increased to $580-$600 million. Stock price rose 23.5% to $11.03 following the earnings report.
